Monotherapy with isoniazid or amikacin or clarithromycin or combinations of two of these drugs showed nil to modest therapeutic activity in beige mice infected with Mycobacterium avium. However, the combination of all three, isoniazid-amikacin-clarithromycin, markedly reduced CFUs in both spleens and lungs after 91 days of infection.
injected with saline. At various times, some mice were sacrificed for CFU determination; to reduce the carryover effect of drugs in the organs, mice were sacrificed 72 h after the last dose.
CFU counts of MAC strain 900 in the spleens, lungs, and livers of mice receiving monotherapy with CLA, EMB, AMI, or INH for 56 days are shown in Table 1 . The organism efficiently multiplied in control mice, as shown by a CFU increase of approximately 3 log 10 CFUs in spleens and livers and 2 log 10 CFUs in lungs. No mortality was observed both in untreated and treated mice (six mice/group). Compared to day 1 counts, bactericidal effects of CLA, EMB, AMI, and INH in spleens and livers (P Ͻ 0.01) (Student's t test) were observed. In lungs, while CLA, AMI, and EMB were bacteriostatic, INH failed to limit mycobacterial proliferation. These results are in keeping with current knowledge on relevant anti-MAC activities of CLA, AMI, and EMB (9) alone but also showed some in vivo activity of INH. To investigate further this novel finding, in particular whether it could be dependent on the strain and the length of the treatment, and also to evaluate the potential use of INH in combined regimens, a MAC strain (strain 905) which is more resistant to those drugs than MAC 900 was tested.
CFU counts in mice infected with MAC 905 receiving therapy with CLA, AMI, EMB, INH, INH-CLA, INH-AMI, CLA-AMI, INH-AMI-CLA, and INH-EMB-CLA for 91 days are shown in Fig. 1 (spleens) and Fig. 2 (lungs). MAC efficiently multiplied in control mice, with a mean increase of 4.71 and 4.93 log 10 CFUs in spleens and lungs, respectively. During the period of observation, 3 (17.6%) of the 17 untreated mice died, while in the drug-treated groups (10 to 16 mice per group), mortality ranged from 0 to 42.9%; mortality of mice treated with all three drugs, INH-AMI-CLA, was 18.7%. Compared with day 1 counts, monotherapy with EMB or INH partially inhibited MAC growth while CLA was bacteriostatic in spleens and lungs and AMI displayed modest but significant degrees of bactericidal activity (P Ͻ 0.05) in spleens. While the two-drug combination INH-CLA was bacteriostatic in both organs, INH-AMI and CLA-AMI were bactericidal (P Ͻ 0.01) in lungs and spleens, respectively, and regrowth was consistently observed after day 42 in spleens and lungs treated with INH-AMI and CLA-AMI, respectively. Unlike the two-drug combinations, the three-drug combination INH-AMI-CLA was significantly (P Ͻ 0.01) bactericidal in both organs and caused Ն2 and Ն6.7 log 10 CFU reductions in comparison with day 1 and day 91 control CFUs, respectively. The three-drug combina-tion INH-EMB-CLA was less effective than INH-AMI-CLA in both organs. No MAC 905 drug-resistant mutant was selected in spleens after 91 days of therapy with combined regimens, as observed by plating dilutions of homogenates onto Middlebrook 7H10 medium containing drug concentrations corresponding to eight times the MICs (results not shown).
The finding that the activity of INH alone was modest or nil is possibly related to the MIC for the strain. Indeed, MAC strain 101 (MIC of INH of 12.5 g/ml) (13) was inhibited at a lower level than MAC strain 905 in beige mice, but the results of those researchers are hardly comparable to our own results due to differences in dosage and duration of treatment. These investigators demonstrated that the combination of INH with the aminoglycoside streptomycin consistently decreased MAC strain 101 CFUs (13) . Our study shows that the combination of INH with the aminoglycoside AMI is significantly more active than AMI alone in lungs (P Ͻ 0.01), but we found that the addition of CLA to INH-AMI markedly decreased CFUs in both organs. The strong activity in vivo of the combination INH-AMI-CLA is in good accordance with our previous results in human macrophages (3) . Coupled with the fact that this therapeutic activity is seen in mice with deficiencies of natural immunity, the data support the notion that this combination could be useful for therapy. 
